VUZE Medical has received 510(k) clearance from the US Food and Drug Administration (FDA) for its second-generation VUZE system, as per a recent press release from the company.

A recent @SpinalNewsInt guest article saw Arthur L Jenkins III outline what he perceives as the current and future landscape of #Spinal surgery—outlining existing and novel technologies, as well as the potential impact of malpractice premiums in the USA.

.@CentinelSpine recently announced the completion of the 5,000th case in the USA with its prodisc C Vivo and prodisc C SK cervical total disc replacement (TDR) technologies, which are part of the company's new Match-the-Disc system.

RT @DrFehlings: Thank you @SpinalNewsInt for this great article!!. New clinical practice guidelines aim to standardise spinal cord injury c….

.@Woven_Ortho announced recently that it has received its second 510(k) clearance from the US Food and Drug Administration for the use of the Ogmend implant enhancement system in spine surgery.

In a guest piece for @SpinalNewsInt, @carlstommy outlines the potential offered by the continued growth of intraoperative imaging and #ArtificialIntelligence technologies for treating adult #Spinal deformity.@Proprio_Vision .

Spineart has announced that it has successfully raised CHF20 million in convertible financing—an announcement that follows the completion of enrolment in the company’s two BAGUERA C investigational device exemption (IDE) studies.

.@onwdempowered announced recently that it has been awarded Breakthrough Device designation (BDD) by the US Food and Drug Administration (FDA) for the ARC-BCI system.

.@theradaptive recently gained approval from the US Food and Drug Administration (FDA) for its investigational device exemption (IDE) submission to begin enrolling patients into OASIS—a global Phase I/II feasibility study in spine fusion.

Researchers in Italy have demonstrated that an innovative nanovector (nanogel)—which they developed—is able to deliver anti-inflammatory drugs in a targeted manner into glial cells actively involved in the evolution of #Spinal cord injury.

Researchers at @MUSChealth have retrospectively compared the operative microscope to the 3D exoscope in a study of spine surgery procedures, now published in @WorldNeurosurg, and found potentially better outcomes for surgeons/patients alike with the latter.

3Spine has announced the achievement of completed US clinical trial enrolment, with 151 completed MOTUS lumbar total joint replacement surgeries and 174 real-world posterior lumbar fusions—as of December 2023.

SynerFuse has announced the appointment of Rohan Lall (M Health Fairview Neurosurgery, Princeton, USA) as the company’s chief medical officer, effective since 2 January 2024.

Cerapedics has today announced that it has filed the final module in a premarket approval (PMA) application with the US Food and Drug Administration (FDA) for its investigational P-15 peptide enhanced bone graft.

.@mirusmed has announced that it has gained @US_FDA 510(k) clearance for its CYGNUS MoRe anterior cervical plate and Mirus 3DR lateral lumbar interbody fusion system with integrated MoRe plate fixation.

.@NovapproachS recently announced the full market launch of its patented OneLIF interbody spinal fusion system during the 2023 @NASSspine annual meeting.

.@Silony_Medical has announced that it has completed the acquisition of @CentinelSpine's Global Fusion Business and related assets.

Some 40% of patients in a recent @EurSpineJournal study underwent #Spinal surgery without reading the informed consent document/being aware of procedural risks. Lead author @JorgeH_NunezCOT outlines the significance of these findings for @SpinalNewsInt .

.@CerapedicsInc has announced long-term follow-up data from its pivotal IDE study of the i-FACTOR peptide-enhanced bone graft, demonstrating fusion rates in single-level ACDF of 98.6% after six years.

Zoher Ghogawala was named president of @NASSspine during the society’s recent 38th annual meeting in Los Angeles, USA.#NASS2023 @NASSJournal @TuftsMedSchool @LaheyHospital .